STOCK TITAN
  1. Home
  2. News
  3. HUGE

FSD Pharma Inc. Class B Subordinate Voting Shares - HUGE STOCK NEWS

Welcome to our dedicated page for FSD Pharma Class B Subordinate Voting Shares news (Ticker: HUGE), a resource for investors and traders seeking the latest updates and insights on FSD Pharma Class B Subordinate Voting Shares stock.

FSD Pharma Inc. (symbol: HUGE) is a leading biopharmaceutical company headquartered in Toronto, Canada. Originally founded in 1998, FSD Pharma is committed to developing innovative treatments for complex neuropsychiatric, neurodegenerative, and inflammatory disorders. The company operates through two main segments: Biopharmaceutical and Strategic Investments.

FSD Pharma, through its subsidiary FV Pharma Inc., focuses on producing medical-grade cannabis in Canada. The company is heavily involved in the research and development of cannabinoid-based therapies targeting central nervous system disorders, autoimmune diseases affecting the skin, gastrointestinal tract, and musculoskeletal system, such as chronic pain.

The company's core development pipeline includes FSD201, an ultra-micronized formulation of PEA, designed to treat inflammatory diseases, along with Lucid-Psych for mental health disorders and Lucid-MS for neurodegenerative conditions. FSD Pharma has formed strategic alliances with companies like SciCann Therapeutics Inc., Canntab Therapeutics, and Solarvest BioEnergy Inc. to bolster its research capabilities and expand its product portfolio.

One of the company's notable breakthroughs is the development of unbuzzd™, a proprietary blend of vitamins, minerals, and botanical extracts that aids in alcohol metabolism and mental alertness. This formulation has been licensed to Celly Nutrition Corp., which is responsible for its market launch in the United States.

FSD Pharma has been actively engaging in clinical trials to validate the efficacy and safety of its products. Recently, the company announced a Phase 1 trial for Lucid-MS aimed at evaluating its potential to prevent and reverse myelin degradation in multiple sclerosis. Another significant milestone is the METAL-2 trial, conducted in collaboration with the Applied Science and Performance Institute (ASPI), which aims to test the safety and efficacy of unbuzzd™.

FSD Pharma is also making strides in strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which involves loans secured by residential or commercial properties. This diversified approach ensures a steady stream of funding for its core research and development activities.

In terms of financial health, FSD Pharma maintains a robust portfolio and is well-positioned to capitalize on future growth opportunities. The company has demonstrated a consistent commitment to advancing science and improving patient outcomes through its innovative biopharmaceutical solutions.

News

FSD Pharma Announces US ATM Offering

Rhea-AI Summary
FSD Pharma Inc. announces an at-the-market offering agreement with H.C. Wainwright & Co., LLC, for Class B Subordinate Voting Shares, with an aggregate offering price of up to US$11,154,232. The sales will be made through Wainwright as the sales agent, in line with Rule 415(a)(4) on Nasdaq. The proceeds will be used for clinical studies, trials, development programs, research, development, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.19%
Tags
none
-
News

Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million

Rhea-AI Summary
FSD Pharma Inc. announced that the Court of Appeal for Ontario affirmed a judgment in the amount of CDN $2.81 million, plus $175,000, plus interest. An additional $5,000 in costs were awarded to FSD Pharma by the Court of Appeal in respect of Dr. Raza Bokhari's failed motion for leave to appeal. The judgment confirmed Arbitration Awards in which the Arbitrator dismissed Dr. Raza Bokhari's claims for wrongful dismissal, and awarded FSD Pharma its fees and costs incurred in defending the arbitration. In December 2023, FSD Pharma filed a Petition to Confirm Arbitration Awards in the United States District Court for the Eastern District of Pennsylvania.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
none
-
News

FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates

Rhea-AI Summary
FSD Pharma Inc. welcomes Dr. Sanjiv Chopra to its board of directors, replacing Nitin Kaushal. The company has also retained the services of multiple firms to enhance market awareness and investor relations. Dr. Chopra's extensive medical background and the strategic partnerships with SBS Intl Group LLC, Draper, Inc., Carriage House Capital, Corp., IR Agency, Beyond Media, and Issuer Direct are the key highlights of the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
management
News

Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot

Rhea-AI Summary
FSD Pharma Inc. provides an update on its litigation with GBB Drink Lab, Inc., denying allegations of breach of mutual nondisclosure agreement and trade secret misappropriation. The Court denied the Motion to Dismiss, allowing FSD Pharma to proceed with discovery to demonstrate the lack of merit in GBB's claims. GBB subsequently sold its assets to Jupiter Wellness, Inc. and changed its name to Safety Shot, Inc. FSD Pharma remains confident in its decision not to acquire GBB.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
-
News

FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC

Rhea-AI Summary
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) has filed a final short form base shelf prospectus to provide the Company with the flexibility to take advantage of financing opportunities and favourable market conditions, enabling the offer, issue, and sale of Securities for up to an aggregate offering amount of US$50,000,000 over a 25-month period. The Registration Statement containing a base shelf prospectus with the SEC has also been filed, allowing the offer, issue, and sale of Securities up to an aggregate amount of US$50,000,000 for a period of three years. The Company has not entered into any agreements or arrangements to authorize or offer any securities at this time, and the net proceeds from the sale of Securities will be used as outlined in the Prospectus and Registration Statement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
none
-
News

FSD Pharma Inc. Announces Closing of Private Placement

Rhea-AI Summary
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) closed a non-brokered private placement and issued 24 class A multiple voting shares at a price of $1.90 per share for gross proceeds of $45.60. The company intends to use the proceeds for general working capital purposes. Insiders, including the CEO, participated in the offering, raising concerns about related-party transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
none
News

FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement

Rhea-AI Summary
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) announced the closing of the proposed distribution of a portion of FSD Pharma's holdings of common shares of Celly Nutrition Corp. to certain securityholders through a statutory plan of arrangement. The distribution resulted in FSD Pharma Securityholders receiving Celly Nu Shares and New FSD Pharma Securities in exchange for their Class A Shares, Class B Shares, and FSD Pharma Distribution Warrants. The Celly Nu Shares distributed are subject to restrictions on resale until May 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness

Rhea-AI Summary
FSD Pharma Inc. (HUGE) provides an update on its litigation with GBB Drink Lab, Inc. regarding alleged breach of mutual nondisclosure agreement and trade secret misappropriation. GBB continues to intimidate competitors and critics through threats of litigation, including Capybara Research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.35%
Tags
none
-
News

FSD Pharma Inc. Obtains Final Order for Plan of Arrangement

Rhea-AI Summary
FSD Pharma Inc. (HUGE) obtained a final order from the Ontario Superior Court of Justice approving the statutory plan of arrangement to distribute Celly Nutrition Corp. shares to FSD Pharma Securityholders. The special resolution to authorize the Arrangement was approved on November 20, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
News

Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.

Rhea-AI Summary
Goldman Small Cap Research has published a new research report on FSD Pharma, Inc. (HUGE) highlighting its innovative biopharmaceutical products, including a patented compound for multiple sclerosis and a functional beverage for relieving the effects of alcohol consumption. The report includes a price target and emphasizes the company's potential for substantial growth and market penetration. FSD Pharma is also set to go ex-dividend on November 27, 2023, rewarding shareholders with stock in the firm launching the UNBUZZD product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
none

FAQ

What is the current stock price of FSD Pharma Class B Subordinate Voting Shares (HUGE)?

The current stock price of FSD Pharma Class B Subordinate Voting Shares (HUGE) is $0.1381 as of August 15, 2024.

What is the market cap of FSD Pharma Class B Subordinate Voting Shares (HUGE)?

The market cap of FSD Pharma Class B Subordinate Voting Shares (HUGE) is approximately 63.7K.

What does FSD Pharma Inc. specialize in?

FSD Pharma Inc. specializes in developing innovative treatments for neuropsychiatric, neurodegenerative, and inflammatory disorders.

What are the core products of FSD Pharma?

Core products include FSD201 for inflammatory diseases, Lucid-Psych for mental health disorders, and Lucid-MS for neurodegenerative conditions.

What is unbuzzd™?

unbuzzd™ is a proprietary blend of vitamins, minerals, and botanical extracts designed to aid in alcohol metabolism and mental alertness.

Who are the strategic partners of FSD Pharma?

FSD Pharma has strategic alliances with SciCann Therapeutics Inc., Canntab Therapeutics, and Solarvest BioEnergy Inc.

Where is FSD Pharma headquartered?

FSD Pharma is headquartered in Toronto, Canada.

What recent clinical trials has FSD Pharma announced?

FSD Pharma recently announced a Phase 1 trial for Lucid-MS and the METAL-2 trial for unbuzzd™.

What is FSD201?

FSD201 is an ultra-micronized formulation of PEA, developed for the treatment of inflammatory diseases.

How does FSD Pharma generate revenue?

FSD Pharma generates revenue through product sales, strategic partnerships, and its subsidiary, FSD Strategic Investments Inc.

What is the significance of Lucid-MS?

Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

What are FSD Pharma's goals?

FSD Pharma aims to advance science and improve patient outcomes through its innovative biopharmaceutical solutions.

Stock HUGE logo
FSD Pharma Inc. Class B Subordinate Voting Shares

Nasdaq:HUGE

HUGE Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

HUGE Stock Data

63.71k
42.75M
9.74%
2.69%
0.38%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Toronto